Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-on study of intravenous efgartigimod in pediatric generalized myasthenia gravis
2021-002460-46Phase 2Active
- Sponsor
- argenx
- Start
- Feb 2022
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of efgartigimod alfa in myasthenia gravis (MG), sponsored by argenx. Primary endpoint: Incidence and severity of adverse events. Started Feb 2022; status: active.
02
Drugs
efgartigimod alfa
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on 2021-002460-46.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002460-46.